Delivery Order SPE2DB20D3101-SPE2DB25FRGK2

Award Date 4/9/25
Potential Completion Date 4/10/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4 mg naloxone hydrochloride nasal spray, a critical medication used to treat opioid overdoses. The contract has a firm fixed price of $1,342.48 and a period of performance through March 27, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4 mg Naloxone Hydrochloride Nasal Spray, a critical medication used for the treatment of opioid overdose. The Delivery Order has a Firm Fixed Price of $2,926.80 and a completion date of February 14, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4 mg Naloxone Hydrochloride nasal spray, a critical medication used to treat opioid overdoses. The contract has a ceiling value of $1,630.20 and an ultimate completion date of January 30, 2025. This order is placed under a larger Indefinite Delivery Contract (IDC) held by...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,061.84, is for the delivery of 4,567,475,840 units of Naloxone HCL 4 mg nasal spray, a critical medication used in the treatment of opioid overdoses. The contract is a firm-fixed-price delivery order with a period of performance through March 6, 2025. This award is part of a larger Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,559,464,440 units of 4 mg Naloxone HCl nasal spray, a critical medication used to treat opioid overdoses. The contract has a ceiling value of $2,737.24 and an ultimate completion date of December 29, 2022. This award is part of a larger Indefinite Delivery Contract (IDC)...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,364.04 firm fixed-price award is for the supply of 4,567,104,095 units of 4 mg naloxone hydrochloride nasal spray, which is a critical medication used to reverse opioid overdoses. The award is not designated under any set-aside program, indicating open competition. This delivery order is part of a larger Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,524.80 firm fixed-price contract is for the supply of 4 mg naloxone hydrochloride nasal spray, a critical medication used to treat opioid overdoses. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg naloxone hydrochloride nasal spray. The delivery order has a not-to-exceed value of $1,879.80 and is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999. This IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a $2,320.69 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide 4,565,664,956 units of 4 mg naloxone hydrochloride nasal spray. This order is part of a larger indefinite delivery contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,342.40 firm fixed price contract is for the delivery of 4 mg naloxone hydrochloride nasal spray, a critical medication used to reverse opioid overdoses. The contract has a period of performance through March 2025 and is not designated as a set-aside award. AmerisourceBergen holds a significant $999,999,999 Indefinite...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB25FRGK2
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for $1,359.46. The order is for the supply of 4 mg nasal spray naloxone hydrochloride, a medication used to treat opioid overdose. The delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which covers a broad range of pharmaceutical products and medical supplies for military healthcare programs. This contract award does not have a set-aside designation, indicating open competition. The contract has an ultimate completion date of April 10, 2025.

Generated 7/9/25, 10:07 AM